NASDAQ : QNRX
Quoin Pharmaceuticals, Ltd. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.54 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 21.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 21.81M |
| Enterprise Value | 13.03M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 4.80M |
| Shares Change (YoY) | +485.24% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 3.67% |
| Owned by Institutions (%) | 27.74% |
| Float | 4.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.32 |
| P/TBV Ratio | 6.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.76 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -575.73% |
| Return on Assets (ROA) | -114.60% |
| Return on Invested Capital (ROIC) | -214.99% |
| Return on Capital Employed (ROCE) | -357.43% |
| Weighted Average Cost of Capital (WACC) | 12.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.11M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -63.09% |
| 50-Day Moving Average | 5.43 |
| 200-Day Moving Average | 6.05 |
| Relative Strength Index (RSI) | 49.31 |
| Average Volume (20 Days) | 32,504 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20,231 |
| Short Previous Month | 65,473 |
| Short % of Shares Out | 0.44% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.41 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.15M |
| Pretax Income | -18.67M |
| Net Income | -18.67M |
| EBITDA | -19.05M |
| EBIT | -19.15M |
| Earnings Per Share (EPS) | -$8.52 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 10.80M |
| Total Debt | 2.02M |
| Net Cash | 8.78M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 3.93M |
| Book Value Per Share | 1.96 |
| Working Capital | 5.02M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -15.27M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 100,000 |
| Net Borrowing | -600,000 |
| Free Cash Flow | -15.27M |
| FCF Per Share | -$3.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -485.24% |
| Shareholder Yield | n/a |
| Earnings Yield | -187.69% |
| FCF Yield | -70.03% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $20.38 |
| Price Target Difference | 348.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 9, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:35 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |